

# Ardex (Ardex Australia)

Chemwatch: 5156-37 Version No: 8.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Chemwatch Hazard Alert Code: 2 Issue Date: 10/03/2023 Print Date: 15/06/2023 L.GHS.AUS.EN.E

# SECTION 1 Identification of the substance / mixture and of the company / undertaking

# Product Identifier

Product name	Ardex RA 54 Part B
Chemical Name	Not Applicable
Synonyms	Not Available
Chemical formula	Not Applicable
Other means of identification	Not Available

# Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Joint treatment.

# Details of the manufacturer or supplier of the safety data sheet

Registered company name	Ardex (Ardex Australia)	
Address	20 Powers Road Seven Hills NSW 2147 Australia	
Telephone	1800 224 070	
Fax	1300 780 102	
Website	www.ardexaustralia.com	
Email	technicalservices@ardexaustralia.com	

# Emergency telephone number

Association / Organisation	Ardex (Ardex Australia)	
Emergency telephone numbers	1800 224 070 (Mon-Fri, 9am-5pm)	
Other emergency telephone numbers	Not Available	

# **SECTION 2 Hazards identification**

### Classification of the substance or mixture

# HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

# Chemwatch Hazard Ratings

	Min	Max	
Flammability	1 📃		
Toxicity	1		0 = Minimum
Body Contact	2	1	1 = Low
Reactivity	1 📃		2 = Moderate
Chronic	2	1	3 = High 4 = Extreme

Poisons Schedule	S5
Classification <sup>[1]</sup>	Skin Corrosion/Irritation Category 2, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2A, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Germ Cell Mutagenicity Category 2, Carcinogenicity Category 2, Hazardous to the Aquatic Environment Long-Term Hazard Category 3
Legend:	1. Classified by Chernwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

Hazard pictogram(s)	

Warning

Signal word

# Hazard statement(s)

H315	Causes skin irritation.		
H317	May cause an allergic skin reaction.		
H319	Causes serious eye irritation.		
H335	May cause respiratory irritation.		
H341	Suspected of causing genetic defects.		
H351	H351 Suspected of causing cancer.		
H412	Harmful to aquatic life with long lasting effects.		

# Precautionary statement(s) Prevention

P201	Obtain special instructions before use.	
P271	Use only outdoors or in a well-ventilated area.	
P280	Wear protective gloves, protective clothing, eye protection and face protection.	
P261	Avoid breathing mist/vapours/spray.	
P273	Avoid release to the environment.	
P264	Wash all exposed external body areas thoroughly after handling.	
P272	P272 Contaminated work clothing should not be allowed out of the workplace.	

# Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.	
P302+P352	IF ON SKIN: Wash with plenty of water and soap.	
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.	
P312	Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.	
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.	
P337+P313	If eye irritation persists: Get medical advice/attention.	
P362+P364	Take off contaminated clothing and wash it before reuse.	
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.	

## Precautionary statement(s) Storage

P405	Store locked up.	
P403+P233	Store in a well-ventilated place. Keep container tightly closed.	

# Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

# **SECTION 3 Composition / information on ingredients**

#### Substances

See section below for composition of Mixtures

# Mixtures

CAS No	%[weight]	Name
8001-79-4	50-75	castor oil
102093-68-5	5-10	2.6-bis(methylthio)-4-methyl-1,3-benzenediamine
13463-67-7	3-5	titanium dioxide
104983-85-9	1-3	4,6-bis(methylthio)-2-methyl-1,3-benzenediamine
1333-86-4	0.3-1	carbon black
Legend:	1. Classified by Chernwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	

# **SECTION 4 First aid measures**

Description of first aid measures				
Eye Contact	<ul> <li>If this product comes in contact with the eyes:</li> <li>Wash out immediately with fresh running water.</li> <li>Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> </ul>			

Page 3 of 15

Comment

B, NS, SQ

# Ardex RA 54 Part B

	<ul> <li>Seek medical attention without delay; if pain persists or recurs seek medical attention.</li> <li>Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
Skin Contact	<ul> <li>If skin contact occurs:</li> <li>Immediately remove all contaminated clothing, including footwear.</li> <li>Flush skin and hair with running water (and soap if available).</li> <li>Seek medical attention in event of irritation.</li> </ul>
Inhalation	<ul> <li>If fumes or combustion products are inhaled remove from contaminated area.</li> <li>Lay patient down. Keep warm and rested.</li> <li>Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.</li> <li>Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary.</li> <li>Transport to hospital, or doctor, without delay.</li> </ul>
Ingestion	<ul> <li>For advice, contact a Poisons Information Centre or a doctor at once.</li> <li>Urgent hospital treatment is likely to be needed.</li> <li>If swallowed do NOT induce vomiting.</li> <li>If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> <li>Observe the patient carefully.</li> <li>Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.</li> <li>Give water to rinse out mouth, then provide liquid slowly and as much as casuality can comfortably drink.</li> <li>Transport to hospital or doctor without delay.</li> </ul>

### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

The material may induce methaemoglobinaemia following exposure.

- Initial attention should be directed at oxygen delivery and assisted ventilation if necessary. Hyperbaric oxygen has not demonstrated substantial benefits.
- + Hypotension should respond to Trendelenburg's position and intravenous fluids; otherwise dopamine may be needed.
- Symptomatic patients with methaemoglobin levels over 30% should receive methylene blue. (Cyanosis, alone, is not an indication for treatment). The usual dose is 1-2 mg/kg of a

Sampling Time

During or end of shift

1% solution (10 mg/ml) IV over 50 minutes; repeat, using the same dose, if symptoms of hypoxia fail to subside within 1 hour.
Thorough cleansing of the entire contaminated area of the body, including the scalp and nails, is of utmost importance.

Index

BIOLOGICAL EXPOSURE INDEX - BEI

These represent the determinants observed in specimens collected from a healthy worker exposed at the Exposure Standard (ES or TLV):

1.5% of haemoglobin

Determinant

1. Methaemoglobin in blood

B: Background levels occur in specimens collected from subjects NOT exposed

NS: Non-specific determinant; also observed after exposure to other materials

SQ: Semi-quantitative determinant - Interpretation may be ambiguous; should be used as a screening test or confirmatory test.

## **SECTION 5 Firefighting measures**

### Extinguishing media

- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.Water spray or fog Large fires only.

#### Special hazards arising from the substrate or mixture

Fire Incompatibility	Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
ice for firefighters	
Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear full body protective clothing with breathing apparatus.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>Use water delivered as a fine spray to control fire and cool adjacent area.</li> <li>Avoid spraying water onto liquid pools.</li> <li>DO NOT approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> </ul>
Fire/Explosion Hazard	<ul> <li>Combustible.</li> <li>Slight fire hazard when exposed to heat or flame.</li> <li>Heating may cause expansion or decomposition leading to violent rupture of containers.</li> <li>On combustion, may emit toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> <li>Mists containing combustible materials may be explosive.</li> <li>Combustion products include:</li> <li>carbon dioxide (CO2)</li> <li>acrolein</li> <li>nitrogen oxides (NOx)</li> <li>sulfur oxides (SOx)</li> <li>other pyrolysis products typical of burning organic material.</li> <li>May emit corrosive fumes.</li> <li>CARE: Water in contact with hot liquid may cause foarning and a steam explosion with wide scattering of hot oil and possible severe burns.</li> </ul>
	Not Applicable

#### **SECTION 6** Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

# Environmental precautions

See section 12

Minor Spills	<ul> <li>Slippery when spilt.</li> <li>Remove all ignition sources.</li> <li>Clean up all spills immediately.</li> <li>Avoid breathing vapours and contact with skin and eyes.</li> <li>Control personal contact with the substance, by using protective equipment.</li> <li>Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>Wipe up.</li> <li>Place in a suitable, labelled container for waste disposal.</li> </ul>
Major Spills	<ul> <li>Slippery when spilt.</li> <li>Moderate hazard.</li> <li>Clear area of personnel and move upwind.</li> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Increase ventilation.</li> <li>Stop leak if safe to do so.</li> <li>Contain spill with sand, earth or vermiculite.</li> <li>Collect recoverable product into labelled containers for recycling.</li> <li>Absorb remaining product with sand, earth or vermiculite.</li> <li>Collect solid residues and seal in labelled drums for disposal.</li> <li>Wash area and prevent runoff into drains.</li> <li>If contamination of drains or waterways occurs, advise emergency services.</li> </ul>

Personal Protective Equipment advice is contained in Section 8 of the SDS.

# **SECTION 7 Handling and storage**

# Precautions for safe handling

	Rags wet / soaked with unsaturated hydrocarbons / drying oils may auto-oxidise; generate heat and, in-time, smoulder and ignite. This is especially the case where oil-soaked materials are folded, bunched, compressed, or piled together - this allows the heat to accumulate or ever accelerate the reaction
Safe handling	<ul> <li>Oily cleaning rags should be collected regularly and immersed in water, or spread to dry in safe-place away from direct sunlight or stored, immersed, in solvents in suitably closed containers.</li> <li>DO NOT allow clothing wet with material to stay in contact with skin</li> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>Avoid smoking, naked lights or ignition sources.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.</li> </ul>
Other information	<ul> <li>Store in original containers.</li> <li>Keep containers securely sealed.</li> <li>No smoking, naked lights or ignition sources.</li> <li>Store in a cool, dry, well-ventilated area.</li> <li>Store away from incompatible materials and foodstuff containers.</li> <li>Protect containers against physical damage and check regularly for leaks.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

# Conditions for safe storage, including any incompatibilities

Suitable container	<ul> <li>Glass container is suitable for laboratory quantities</li> <li>Metal can or drum</li> <li>Packaging as recommended by manufacturer.</li> <li>Check all containers are clearly labelled and free from leaks.</li> </ul>
Storage incompatibility	<ul> <li>Avoid cross contamination between the two liquid parts of product (kit).</li> <li>If two part products are mixed or allowed to mix in proportions other than manufacturer's recommendation, polymerisation with gelation and evolution of heat (exotherm) may occur.</li> <li>This excess heat may generate toxic vapour</li> <li>Avoid oxidising agents, acids, acid chlorides, acid anhydrides, chloroformates.</li> </ul>

# **SECTION 8 Exposure controls / personal protection**

# **Control parameters**

Occupational Exposure Limits (OEL)

# INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	titanium dioxide	Titanium dioxide	10 mg/m3	Not Available	Not Available	<ul> <li>(a) This value is for inhalable dust containing no asbestos and &lt; 1% crystalline silica.</li> </ul>
Australia Exposure Standards	carbon black	Carbon black	3 mg/m3	Not Available	Not Available	Not Available

# Emergency Limits

Ingredient	TEEL-1 TEEL-2			TEEL-3		
titanium dioxide	30 mg/m3	330 mg/m3		2,000 mg/m3		
carbon black	9 mg/m3	9 mg/m3 99 mg/m3		590 mg/m3		
Ingredient	Original IDLH		Revised IDLH			
castor oil	Not Available		Not Available	Not Available		
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	Not Available		Not Available	Not Available		
titanium dioxide	5,000 mg/m3		Not Available	Not Available		
4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	Not Available	Not Available		Not Available		
carbon black	1,750 mg/m3		Not Available	Not Available		

# Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit	
castor oil	E	≤ 0.1 ppm	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	D	> 0.1 to ≤ 1 ppm	
4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	E	≤ 0.1 ppm	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a		

adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds range of exposure concentrations that are expected to protect worker health.

# MATERIAL DATA

# Exposure controls

	Care: Atmospheres in bulk storages and even apparently empty tanks may be hazardous by oxygen depletion. Atmosphere must be checked before entry.						
	Requirements of State Authorities concerning conditions for tank entry must be met. Particularly with regard to training of crews for tank entry; work permits; sampling of atmosphere; provision of rescue harness and protective gear as needed Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls of be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategical "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.						
	Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. An approved self contained breathing apparatus (SCBA) may be required in some situations. Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.						
	Type of Contaminant:	Air Speed:					
Appropriate engineering controls	solvent, vapours, degreasing etc., evaporating from tank (in	0.25-0.5 m/s (50-100 f/min.)					
	aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)						
	direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)						
	grinding, abrasive blasting, tumbling, high speed wheel ger very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)					
	Within each range the appropriate value depends on:						
		Upper end of the range					
	Lower end of the range						
	Lower end of the range 1: Room air currents minimal or favourable to capture	1: Disturbing room air currents					
	1: Room air currents minimal or favourable to capture	1: Disturbing room air currents					

	1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.
Individual protection measures, such as personal protective equipment	
Eye and face protection	<ul> <li>Safety glasses with side shields.</li> <li>Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]</li> <li>Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].</li> </ul>
Skin protection	See Hand protection below
Hands/feet protection	<ul> <li>Wear chemical protective gloves, e.g. PVC.</li> <li>Wear stelly fortwear or safety gumboots, e.g. Rubber</li> <li>NOTE:         <ul> <li>The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.</li> <li>Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.</li> <li>The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.</li> <li>The selection of suitable gloveked prior to the application.</li> <li>The selection durability of glove type is dependent on usage. Important factors in the selection of gloves and has to be observed when making a final choice.</li> <li>Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried throughly. Application of a non-perfumed moisturiser is recommended.</li> <li>Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:</li></ul></li></ul>
<b>_</b>	▶ Neoprene gloves
Body protection	See Other protection below
Other protection	<ul> <li>Overalls.</li> <li>P.V.C apron.</li> <li>Barrier cream.</li> <li>Skin cleansing cream.</li> <li>Eye wash unit.</li> </ul>

# Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index". The effect(s) of the following substance(s) are taken into account in the *computergenerated* selection: Ardex RA 54 Part B

Material	СРІ
NEOPRENE	A

\* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

## **Respiratory protection**

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AK-AUS P2	-	AK-PAPR-AUS / Class 1 P2
up to 50 x ES	-	AK-AUS / Class 1 P2	-

**NOTE:** As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

# up to 100 x ES - AK-2 P2 AK-PAPR-2 P2 ^

# ^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

76ak-p()

## **SECTION 9** Physical and chemical properties

### Information on basic physical and chemical properties

Appearance	Coloured opaque viscous liquid with vegetable oil or	alight aminic adour: doog not mix with	water
Appearance	Coloured opaque viscous liquid with vegetable oil of s	sight aminic odour, does not mix with	water.
Physical state	Liquid	Relative density (Water = 1)	1.08
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	3000-7000
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	>93.3 (CC)	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Immiscible	pH as a solution (1%)	Not Applicable
Vapour density (Air = 1)	Not Available	VOC g/L	<10

## **SECTION 10 Stability and reactivity**

Reactivity	See section 7
Chemical stability	<ul> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

## **SECTION 11 Toxicological information**

#### Information on toxicological effects

Inhaled	Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Inhalation hazard is increased at higher temperatures.
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual.

Skin Contact		individuals following direct contact, and/or ealthy intact skin of animals (for up to four hours), such inflammation re period. sure; this may result in a form of contact dermatitis (nonallergic). The elling (oedema) which may progress to blistering (vesiculation), scaling be intercellular oedema of the spongy layer of the skin (spongiosis) and repeated exposures may produce severe ulceration. al ure wounds or lesions, may produce systemic injury with harmful effects.	
Eye	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals. Repeated or prolonged eye contact may cause inflammation (similar to windburn) characterised by a temporary redness of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.		
Chronic	On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals. Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive. Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances that can cuase occupational asthma and there substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive. Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the deg		
Ardex RA 54 Part B	TOXICITY Not Available	IRRITATION Not Available	
	тохісіту	IRRITATION Eye (rabbit): 500 mg mild	
castor oil	Oral (Rat) LD50: >4800 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild Skin (rabbit): 100 mg/24h SEVERE	
castor oil	Oral (Rat) LD50: >4800 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild	
	Oral (Rat) LD50: >4800 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild	
2,6-bis(methylthio)-4-methyl-		Skin (human): 50 mg/48h mild Skin (rabbit): 100 mg/24h SEVERE	
	τοχιςιτγ	Skin (human): 50 mg/48h mild Skin (rabbit): 100 mg/24h SEVERE IRRITATION	
2,6-bis(methylthio)-4-methyl-	TOXICITY Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup>	Skin (human): 50 mg/48h mild Skin (rabbit): 100 mg/24h SEVERE IRRITATION	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	TOXICITY Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available	
2,6-bis(methylthio)-4-methyl-	TOXICITY         Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup>	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >2.28 mg/4h <sup>[1]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl-	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >2.28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup>	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >2.28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         IRRITATION	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl-	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=2.28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[2]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         IRRITATION         IRRITATION         IRRITATION         IRRITATION         IRRITATION         IRRITATION	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl-	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup>	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine carbon black	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=2.28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> Skin: no adverse effect observed (not irritating) <sup>[1]</sup> Skin: no adverse effect observed (not irritating) <sup>[1]</sup>	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup>	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Skin: no adverse effect observed (not irritating) <sup>[1]</sup>	
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine titanium dioxide 4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine carbon black	TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           dermal (hamster) LD50: >=10000 mg/kg <sup>[2]</sup> Inhalation(Rat) LC50: >=2.28 mg/l4h <sup>[1]</sup> Oral (Rat) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >=2000 mg/kg <sup>[1]</sup> TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[2]</sup> Oral (Rat) LD50: 1515 mg/kg <sup>[2]</sup> TOXICITY           Dermal (rabbit) LD50: >2000 mg/kg <sup>[1]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[1]</sup> Oral (Rat) LD50: >2000 mg/kg <sup>[1]</sup> 1. Value obtained from Europe ECHA Registered Substances - Acute tox	Skin (human): 50 mg/48h mild         Skin (rabbit): 100 mg/24h SEVERE         IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> Skin (human): 0.3 mg /3D (int)-mild *         Skin: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Eye: no adverse effect observed (not irritating) <sup>[1]</sup> IRRITATION         Not Available         IRRITATION         Skin: no adverse effect observed (not irritating) <sup>[1]</sup>	

following administration of high doses (salivation, diarrhoea, staining, piloerection and lethargy). There were no adverse effects on body weight in any study In some studies, excess test substance and/or irritation in the gastrointestinal tract was observed at necropsy. Skin and eye irritation potential, with a few stated exceptions, is chain length dependent and decreases with increasing chain length According to several OECD test regimes the animal skin irritation studies indicate that the C6-10 aliphatic acids are severely irritating or corrosive, while the C12 aliphatic acid is irritating, and the C14-22 aliphatic acids generally are not irritating or mildly irritating. Human skin irritation studies using more realistic exposures (30-minute,1-hour or 24-hours) indicate that the aliphatic acids have sufficient, good or very good skin compatibility. Animal eye irritation studies indicate that among the aliphatic acids, the C8-12 aliphatic acids are irritating to the eye while the C14-22 aliphatic acids are not irritating Eye irritation potential of the ammonium salts does not follow chain length dependence; the C18 ammonium salts are corrosive to the eyes. Dermal absorption: The in vitro penetration of C10. C12. C14. C16 and C18 fatty acids (as sodium salt solutions) through rat skin decreases with increasing chain length. At 86.73 ug C16/cm2 and 91.84 ug C18/cm2, about 0.23% and less than 0.1% of the C16 and C18 soap solutions is absorbed after 24 h exposure, respectively. Sensitisation: No sensitisation data were located. Repeat dose toxicity Repeated dose oral (gavage or diet) exposure to aliphatic acids did not result in systemic toxicity with NOAELs greater than the limit dose of 1000 mg/kg bw. Mutagenicity Aliphatic acids do not appear to be mutagenic or clastogenic in vitro or in vivo Carcinogenicity No data were located for carcinogenicity of aliphatic fatty acids. Reproductive toxicity No effects on fertility or on reproductive organs, or developmental effects were observed in studies on aliphatic acids and the NOAELs correspond to the maximum dose tested. The weight of evidence supports the lack of reproductive and developmental toxicity potential of the aliphatic acids category. Given the large number of substances in this category, their closely related chemical structure, expected trends in physical chemical properties, and similarity of toxicokinetic properties, both mammalian and aquatic endpoints were filled using read-across to the closest structural analogue, and selecting the most conservative supporting substance effect level. Structure-activity relationships are not evident for the mammalian toxicity endpoints. That is, the low mammalian toxicity of this category of substances limits the ability to discern structural effects on biological activity. Regardless, the closest structural analogue with the most conservative effect value was selected for read across. Irritation is observed for chain lengths up to a cut-off" at or near 12 carbons). Metabolism: The aliphatic acids share a common degradation pathway in which they are metabolized to acetyl-CoA or other key metabolites in all living systems. Common biological pathways result in structurally similar breakdown products, and are, together with the physico-chemical properties, responsible for similar environmental behavior and essentially identical hazard profiles with regard to human health. Differences in metabolism or biodegradability of even and odd numbered carbon chain compounds or saturated/ unsaturated compounds are not expected; even-and odd-numbered carbon chain compounds, and the saturated and unsaturated compounds are naturally occurring and are expected to be metabolized and biodegraded in the same manner. The acid and alkali salt forms of the homologous aliphatic acid are expected to have many similar physicochemical and toxicological properties when they become bioavailable; therefore data read across is used for those instances where data are available for the acid form but not the salt, and vice versa. In the gastrointestinal tract, acids and bases are absorbed in the undissociated (non-ionised) form by simple diffusion or by facilitated diffusion. It is expected that both the acids and the salts will be present in (or converted to) the acid form in the stomach. This means that for both aliphatic acid or aliphatic acid salt, the same compounds eventually enter the small intestine, where equilibrium, as a result of increased pH, will shift towards dissociation (ionised form). Hence, the situation will be similar for compounds originating from acids and therefore no differences in uptake are anticipated Note that the saturation or unsaturation level is not a factor in the toxicity of these substances and is not a critical component of the read across process . Toxicokinetics: The turnover of the [14C] surfactants in the rat showed that there was no significant difference in the rate or route of excretion of 14C given by intraperitoneal or subcutaneous administration. The main route of excretion was as 14CO2 in the expired air at 6 h after administration. The remaining material was incorporated in the body. Longer fatty acid chains are more readily incorporated than shorter chains. At ca. 1.55 and 1.64 mg/kg bw, 71% of the C16:0 and 56% of the C18:0 was incorporated and 21% and 38% was excreted as 14CO2, respectively. Glycidyl fatty acid esters (GEs), one of the main contaminants in processed oils, are mainly formed during the deodorisation step in the refining process of edible oils and therefore occur in almost all refined edible oils. GEs are potential carcinogens, due to the fact that they readily hydrolyze into the free form glycidol in the gastrointestinal tract, which has been found to induce tumours in various rat tissues. Therefore, significant effort has been devoted to inhibit and eliminate the formation of GEs GEs contain a common terminal epoxide group but exhibit different fatty acid compositions. This class of compounds has been reported in edible oils after overestimation of 3-monochloropropane-1,2-diol (3-MCPD) fatty acid esters analysed by an indirect method , 3-MCPD esters have been studied as food processing contaminants and are found in various food types and food ingredients, particularly in refined edible oils. 3-Monochloropropane-1,2-diol (3-MCPD) and 2-monochloropropane-1,3-diol (2-MCPD) are chlorinated derivatives of glycerol (1,2,3propanetriol). 3- and 2-MCPD and their fatty acid esters are among non-volatile chloropropanols, Glycidol is associated with the formation and decomposition of 3- and 2-MCPD. It forms monoesters with fatty acids (GE) during the refining of vegetable oils. Chloropropanols are formed in HVP during the hydrochloric acid-mediated hydrolysis step of the manufacturing process. In food production, chloropropanols form from the reaction of endogenous or added chloride with glycerol or acylglycerol. Although harmful effects on humans and animals have not been demonstrated, the corresponding hydrolysates, 3-MCPD and glycidol, have been identified as rodent genotoxic carcinogens, ultimately resulting in the formation of kidney tumours (3-MCPD) and tumours at other tissue sites (glycidol). Therefore, 3-MCPD and glycidol have been categorised as "possible human carcinogens (group 2B) and "probably carcinogenic to humans (group 2A), respectively, by the International Agency for Research on Cancer (IARC). Diacylglyceride (DAG) based oils produced by one company were banned from the global market due to "high levels" of GEs. Several reports have also suggested that a bidirectional transformation process may occur not only between glycidol and 3-MCPD but also their esterified forms in the presence of chloride ions. The transformation rate of glycidol to 3-MCPD was higher than that of 3-MCPD to glycidol under acidic conditions in the presence of chloride ion. Precursors of GEs in refined oils have been identified as partial acylglycerols, that is, DAGs and monoacylglycerides (MAGs); however, whether they also originate from triacylglycerides (TAGs) is still a topic of controversial debates. Several authors noted that pure TAGs were stable during heat treatment (such as 235 deg C) for 3 h and were therefore not involved in the formation of GEs. However, experimental results have shown that small amounts of GEs are present in a heat-treated oil model consisting of almost 100% TAGs. The formation of GEs from TAGs can be attributed to the pyrolysis of TAGs to DAGs and MAGs. In contrast, 3-MCPD esters in refined oils can be obtained from TAG . Presently, the

mechanism for the formation of GE intermediates and the relationship between GEs and 3-MCPD esters are still unknown For Group E aliphatic esters (polyol esters):

According to a classification scheme described by the American Chemistry Council' Aliphatic Esters Panel, Group E substances are esters of monoacids, mainly common fatty acids, and trihydroxy or polyhydroxyalcohols or polyols, such as pentaerythritol (PE), 2-ethyl-2-(hydroxymethyl)-1,3-propanediol or trimethylolpropane (TMP), and dipentaerythritol (diPE). The Group E substances often are referred to as "polyol esters" The polyol esters are unique in their chemical characteristics since they lack beta-tertiary hydrogen atoms, thus leading to stability against oxidation and elimination. The fatty acids often range from C5-C10 to as high as C18 (e.g., oleic, stearic, isostearic, tall oil fatty acids) in carbon number

and generally are derived from naturally occurring sources. Group E esters may have multiple ester linkages and may include mixed esters derived from different carbon-length fatty acid mixtures. The lack of beta-tertiary hydrogen atoms in the structure of the polyol esters makes them characteristically and chemically stable against oxidation and elimination in comparison to other ester classes or groups. For these reasons, trimethylolpropane (TMP) and pentaerythritol (PE) esters with fatty acids of C5 to C10 carbon-chain length have applications as synthetic lubricants for passenger car motor oil and military and civilian jet engines. TMP and PE esters of C18 acids (e.g., isostearic and oleic acids) also have found use in synthetic lubricant applications, including refrigeration lubricants and hydraulic fluids. Because of their higher thermal stability characteristics, they also find use in a variety of high temperature applications such as industrial oven chain oils, high temperature greases, fire resistant transformer coolants and turbine engines.

Polyol esters that are extensively esterified also have greater polarity, less volatility and enhanced lubricity characteristics. **Acute toxicity:** Depending on the degree of esterification, the polyol esters can be resistant or slow towards chemical or enzymatic hydrolysis (i.e., esterase or lipases) as a result of steric hindrance. PE and diPE esters that are capable of being enzymatically hydrolyzed will generate pentaerythritol or dipentaerythritol, and the corresponding fatty acids which, for most of the Group E esters, are comprised mainly of oleic, linoleic and stearic acids as well as the fatty acids in the C5-10 carbon-length. Similarly, TMP esters can undergo metabolism to yield trimethylolpropane (2-ethyl-2-hydroxymethyl-1,3-propanediol) and fatty acid constituents. Pentaerythritol and trimethylolpropane have been reported to have a low order of

toxicity The acute oral LD50 for these substances was greater than 2000 mg/kg indicating a relatively low order of toxicity. The similarity in the low order of toxicity for these substances is consistent with their similar chemical structure and physicochemical properties.

Metabolic studies of polyglyceryl esters indicated that these esters are hydrolyzed in the gastrointestinal (GI) tract, and utilization and digestibility studies supported the assumption that the fatty acid moiety is metabolized in the normal manner. Analytical studies have produced no evidence of accumulation of the polyglycerol moiety in body tissues.

In an acute dermal toxicity study in rats, the LD50 of 1,2,3-propanetriol, homopolymer, diisooctadecanoate was>5000 mg/kg Low toxicity was reported in acute oral studies. In rats, the LD50 >2000 mg/kg for polyglyceryl-3 caprate, polyglyceryl-3 caprylate, polyglyceryl-4 caprate, diisostearoyl polyglyceryl-3 dimer dilinoleate, and the LD50 was >5000 mg/kg for polyglyceryl-3 iso-stearate, polyglyceryl-3-oleate, polyglyceryl-2 diisostearate and polyglyceryl-3 diisostearate.

The ability to enhance skin penetration was examined for several of the polyglyceryl fatty acid esters.

**Repeat dose toxicity:** Polyol esters are generally well tolerated by rats in 28-day oral toxicity studies. NOAEL for these substances was 1000 mg/kg/day in Sprague-Dawley rats. The TMP ester of heptanoic and octanoic acid did not produce signs of overt systemic toxicity at any dose levels tested (i.e., 100, 300, and 1000 mg/kg/day). There were no treatment-related clinical in-life, functional observation battery, or gross postmortem findings. There were no treatment related mortality, and no adverse effects on body weight, food consumption, clinical laboratory parameters, or organ weights. However, there were increased numbers of hyaline droplets in the proximal cortical tubular epithelium of the 300 and 1000 mg/kg/day in male rats. Based on these findings (hyaline droplets), the NOAEL for this polyol ester

was established at 100 mg/kg/day for male rats. Hyaline droplet formation observed in the male kidneys is believed to be a sex/species condition specific to only male rats, which has little relevance to humans.

The results from these repeated dose dermal toxicity studies suggest that polyol esters exhibit a low order of toxicity following repeated application. This may be attributable to similarities in their chemical structures, physicochemical properties, and common metabolic pathways (i.e., esters can be enzymatically hydrolyzed to the corresponding polyalcohol and the corresponding fatty acids) The polyol, hexanedioic acid, mixed esters with decanoic acid, heptanoic acid, octanoic acid and PE, was applied to the skin of groups of 10 (male and female) rats for five days a week for four (4) weeks at dose levels of 0, 125, 500 and 2000 mg/kg/day. Treated animals exhibited no signs indicative of systemic toxicity. No visible signs of irritation were observed a treatment sites. Microscopically, treated skin (viz., greater than or equal to 500 mg/kg/day) exhibited a dose-related increased incidence and severity of hyperplasia and hyperkeratosis of the epidermis and sebaceous gland hyperplasia. These effects were reversible. None of the minor changes in haematology and serum chemistry parameters were considered biologically significant. High dose females (2000 mg/kg/day) exhibited a significant increase in relative adrenal and brain weights when compared to the controls. These differences were attributed to the lower final body weight of the female animals. The NOAEL in this study for systemic toxicity was established as 500 mg /kg/day and 125 mg/kg/day for skin irritation.

Two 28-day study conducted with fatty acids, C5-10, esters with pentaerythritol (CAS RN: 68424-31-7) and dipentaerythritol ester of n-C5/iso-C9 acids (CAS RN: 647028-25-9) showed no signs of overt toxicity. The 90-day study pentaerythritol ester of pentanoic acids and isononanoic acid (CAS RN: 146289-36-3) did not show any signs of overt toxicity. However, increased kidney and liver weights in the male animals was observed. In conclusion, since the effects observed are not considered to be systemic and relevant for humans, the NOAEL was found to exceed 1000 mg/kg bw for all substances based on the result from the 28 and 90-day studies.

Reproductive and developmental toxicity: Since metabolism of the polyol esters can occur, leading to the generation of the corresponding fatty acids and the polyol alcohol (such as pentaerthyritol, trimethylolpropane, and dipentaerythritol), the issue of whether these metabolites may pose any potential reproductive/developmental toxicity concerns is important. However, the polyol alcohols such as pentaerthyritol, trimethylolpropane, and dipentaerythritol, such as pentaerthyritol, trimethylolpropane, and dipentaerythritol, such as pentaerthyritol, trimethylolpropane, and dipentaerythritol, would be expected to undergo further metabolism, conjugation and excretion in the urine. Available evidence indicates that these ester hydrolysates (i.e., hydrolysis products), primarily fatty acids (e.g., heptanoic, octanoic, and decanoic acids) and secondarily the polyol alcohols should exhibit a low order of reproductive toxicity. it can be concluded that this group of high molecular weight polyol esters should not produce profound reproductive effects in rodents.

Genotoxicity: Polyols tested for genetic activity in the Salmonella assay, have been found to be inactive. Several polyol esters have been adequately tested for chromosomal mutation in the in vitro mammalian chromosome aberration assay, and all were inactive. Two TMP esters were also tested for in vivo chromosomal aberration in rats, and both demonstrated no activity. Thus, it is unlikely that these substances are chromosomal mutagens.

**Carcinogenicity:** In a 2-yr study, 28 male and 28 female rats were fed 5% polyglyceryl ester in the diet. No adverse effects on body weight, feed consumption, haematology values, or survival rate were noted. Liver function tests and renal function tests performed at 59 and 104 wks of the study were comparable between the test group and a control group fed 5% ground nut oil. The carcass fat contained no polyglycerol, and the levels of free fatty acid, unsaponifiable residue and fatty acid composition of carcass fat were not different from the controls. Organ weights, tumour incidence and tumour distribution were similar in control and test groups. A complete histological examination of major organs showed nothing remarkable

For trialvcerides:

Carboxylic acid esters will undergo enzymatic hydrolysis by ubiquitously expressed GI esterases. The rate of hydrolysis is dependant on the structure of the ester, and may therefore be rapid or rather slow. Thus, due to hydrolysis, predictions on oral absorption based on the physicochemical characteristics of the intact parent substance alone may no longer apply.

When considering the hydrolysis product glycerol, absorption is favoured based on passive and active absorption of glycerol. The Cosmetic Ingredient Review (CIR) Expert Panel has issued three final reports on the safety of 25 triglycerides, i.e., fatty acid triesters of glycerin

High purity is needed for the triglycerides. Previously the Panel published a final report on a diglycerides, and concluded that the ingredients in the diglyceride family are safe in the present practices of use and concentration provided the content of 1,2-diesters is not high enough to induce epidermal hyperplasia. The Panel discussed that there was an increased level of concern because of data regarding the induction of protein kinase C (PKC) and the tumor promotion potential of 1,2-diacylglycerols. The Panel noted that, nominally, glyceryl-1,3-diesters contain 1,2-diesters, raising the concern that 1,2-diesters could potentially induce hyperplasia. The Panel did note that these compounds are more likely to cause these effects when the fatty acid chain length is <=14 carbons, when one fatty acid is saturated and one is not, and when given at high doses, repeatedly. Although minimal percutaneous absorption of triolein has been demonstrated in vivo using guinea pigs (but not hairless mice) and in vitro using full-thickness skin from hairless mice, the Expert Panel recognizes that, reportedly, triolein and tricaprylin can enhance the skin penetration of other chemicals, and recommends that care should be exercised in using these and other glyceryl triesters in cosmetic products. The Panel acknowledged that some of the tiglycerides may be formed from plant-derived or animal-derived constituents. The Panel thus expressed concern regarding pesticide residues and heavy metals that may be present in botanical ingredients. They stressed that the cosmetics industry should continue to use the necessary procedures to sufficiently limit amounts of such impurities in an ingredient before blending them

industry should continue to use the necessary procedures to sufficiently limit amounts of such impurities in an ingredient before blending them into cosmetic formulations. Additionally, the Panel considered the risks inherent in using animal-derived ingredients, namely the transmission of infectious agents. Although tallow may be used in the manufacture of glyceryl tallowate and is clearly animal-derived, the Panel notes that tallow is highly processed, and tallow derivatives even more so. The Panel agrees with determinations by the U.S. FDA that tallow derivatives are not risk materials for transmission of infectious agents.

Finally, the Panel discussed the issue of incidental inhalation exposure, as some of the triglycerides are used in cosmetic sprays and could possibly be inhaled. For example, triethylhexanoin and triisostearin are reported to be used at maximum concentrations of 36% and 30%. respectively, in perfumes, and 14.7% and 10.4%, respectively, in face powders. The Panel noted that in aerosol products, 95% - 99% of droplets/particles would not be respirable to any appreciable amount. Furthermore, droplets/particles deposited in the nasopharyngeal or bronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of these ingredients. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects Cosmetic Ingredient Review (CIR) : Amended Safety Assessment of Triglycerides as Used in Cosmetics August 2017 Glyceryl triesters are also known as triglycerides; ingested triglycerides are metabolized to monoglycerides, free fatty acids, and glycerol, all of which are absorbed in the intestinal mucosa and undergo further metabolism. Dermal absorption of Triolein in mice was nil: the oil remained at the application site. Only slight absorption was seen in guinea pig skin. Tricaprylin and other glyceryl triesters have been shown to increase the skin penetration of drugs. Little or no acute, subchronic, or chronic oral toxicity was seen in animal studies unless levels approached a significant percentage of caloric intake. Subcutaneous injections of Tricaprylin in rats over a period of 5 weeks caused a granulomatous reaction characterized by oil deposits surrounded by macrophages. Dermal application was not associated with significant irritation in rabbit skin. Ocular exposures were, at most, mildly irritating to rabbit eyes. No evidence of sensitization or photosensitization was seen in a guinea big maximization test. Most of the genotoxicity test systems were negative. Tricaprylin, Trioctanoin, and Triolein have historically been used as vehicles in carcinogenicity testing of other chemicals. In one study, subcutaneous injection of Tricaprylin in newborn mice produced more tumors in lymphoid tissue than were seen in untreated animals, whereas neither subcutaneous or intraperitoneal injection in 4- to 6-week-old female mice produced any tumors in another study. Trioctanoin injected subcutaneously in hamsters produced no tumors. Trioctanoin injected intraperitoneally in pregnant rats was associated with an increase in mammary tumors in the offspring compared to that seen in offspring of untreated animals, but similar studies in pregnant hamsters and rabbits showed no tumors in the offspring. One study of Triolein injected subcutaneously in rats showed no tumors at the injection site. As part of an effort to evaluate vehicles used in carcinogenicity studies, the National Toxicology Program conducted a 2-year carcinogenicity study in rats given Tricaprylin by gavage. This treatment was associated with a statistically significant dose-related increase in pancreatic acinar cell hyperplasia and adenoma, but there were no acinar carcinomas, the incidence of mononuclear leukemia was less, and nephropathy findings were reduced, all compared to corn oil controls. Overall, the study concluded that Tricaprylin did not offer significant advantages over corn oil as vehicles in carcinogenicity studies. Trilaurin was found to inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil. Tricaprylin was not teratogenic in mice or rats, but some reproductive effects were seen in rabbits. A low level of fetal eye abnormalities and a small percentage of abnormal sperm were reported in mice injected with Trioctanoin as a vehicle control. Clinical tests of Trilaurin at 36.3% in a commercial product applied to the skin produced no irritation reactions. Trilaurin, Tristearin, and Tribehenin at 40%, 1.68%, and 0.38%, respectively, in commercial products were also negative in repeated-insult patch tests. Tristearin at 0.32% in a commercial product induced transient, mild to moderate, ocular irritation after instillation into the eyes of human subjects. Based on the enhancement of penetration of other chemicals by skin treatment with glyceryl triesters, it is recommended that care be exercised in using them in cosmetic products. Cosmetic Ingredient Review (CIR) Expert Panel: Final Report on the Safety Assessment of Trilaurin etc: Int J Toxicol, 20 Suppl 4, 61-94 2001 Some tumorigenic effects have been reported in animal studies using castor oil The castor seed contains ricin, a toxic protein. Heating during the oil extraction process denatures and inactivates the protein. However, harvesting castor beans may not be without risk. Allergenic compounds found on the plant surface can cause permanent nerve damage, making the harvest of castor beans a human health risk The United States Food and Drug Administration (FDA) has categorized castor oil as "generally recognized as safe and effective" (GRASE) for over-the-counter use as a laxative with its major site of action the small intestine where it is digested into ricinoleic acid. Despite castor oil being widely used to start labor in pregnant women, to date there is not enough research to show whether it is effective to ripen the cervix or induce labour Due to its foul taste a heavy dose of castor oil was formerly used as a humiliating punishment for children and adults. Victims of this treatment did sometimes die, as the dehydrating effects of the oil-induced diarrhea; however, even those victims who survived had to bear the humiliation of the laxative effects resulting from excessive consumption of the oil. Several instances of sensitization to castor oil in cosmetics have been reported, including an allergic reaction to a make-up remover and contact dermatitis caused by use of a lipstick containing castor oil . Hypersensitivity reactions such as angioedema, rhinitis, asthma, and scarlatiniform rashes have been reported in factory workers involved in the extraction of castor oil , or in association with ingesting it . Relatively few studies of castor oil toxicity have been conducted with experimental animals, and no studies were located concerning its absorption, distribution, metabolism, or excretion.. Subcutaneous injection of 0.1 ml of castor oil in adult C57Bl/6 mice, daily for 4 weeks, was associated with the presence of electron dense lipid inclusions in parenchymal cells of the zona fasciculata of the adrenal gland . Gavage administration of 1 ml/kg to rhesus monkeys, daily for 4 days, caused mild morphological changes in the small intestine, characterized by lipid droplets along the mucosal epithelium and in the underlying lamina propria. This was considered a possible indication that castor oil had reduced lipid metabolism in the intestinal epithelium. Because of widespread human exposure, large annual production and use, and the lack of studies characterizing the effect of exposures of moderate duration, the subchronic toxicity of castor oil was evaluated by administering diet formulations to F344/N rats and B6C3F1 mice for 13 weeks. Exposure to castor oil in the diet at concentrations up to 10% had no effect on survival of F344/N rats. No significant differences in average food consumption among each sex were observed, although food consumption of male and female rats receiving diets containing 10% castor oil was slightly lower than that of controls. Hematological effects of the castor oil diets among male rats included a slight decrease in MCHC at day 21 in those receiving the 10% diet; a statistically significant decrease in MCV among the 10% group; a decrease in MCH among the 5% and 10% groups; and an increase in platelets among the 1.25%, 5%, and 10% groups. The only change observed among female rats was a statistically significant decrease in reticulocyte counts at day 5 in groups receiving the 0.62% or 10% diets . None of these changes was considered biologically significant. A treatment- and dose-related increase in the activity of serum alkaline phosphatase was observed in male and female rats at days 5 and 21, and at study termination. Total bile acids were increased among males receiving the higher dietary levels at days 5 and 21 but were not increased at study termination. Other minor changes included increases in albumin observed at study termination in males receiving 5% diets and at day 5 in females receiving 10% diets, and an increase in urea nitrogen at study termination in males that received 0.62% diets and a decrease at day 5 in females that received castor oil at 10% in the diet. Absolute liver weights and the liver-to-body-weight ratio were increased in male rats that received diets containing 10% castor oil. Heart-to-body-weight ratios were increased in groups of male rats receiving 0.62% 2.5%, and 10% diets; however, absolute heart weights were not increased, and the differences in body weight ratios were small and not considered treatment related . Using light microscopy, it was determined there were no morphologic changes associated with the slight differences in organ weights between groups. In male rats, there was a slight decrease in epididymal weight (6-7%) which occurred in the middle- and high-dose groups, but this was not dose-related. There were no effects on any other male rat reproductive endpoint, or on any female rat reproductive endpoint. Although there was some variation in epididymal weights, their small magnitude and the absence of changes in other endpoints suggested that there was little or no evidence of any reproductive toxicity associated with castor oil exposure. Histopathologic examination revealed an absence of compoundrelated lesions in any organ or tissue of rats exposed to castor oil in the diet. In genetic toxicity studies, castor oil (100-10,000 ug/plate) was not mutagenic in Salmonella typhimurium strains TA100, TA1535, TA97, or TA98 when tested with a preincubation protocol in the presence and the absence of exogenous metabolic activation (S9). Castor oil did not induce sister-chromatid exchanges or chromosome aberrations in Chinese hamster ovary cells treated with concentrations up to 5000 Og/ml with and without S9. No induction of micronuclei was observed in peripheral blood erythrocytes of male and female B6C3F1 mice sampled at the termination of the 13-week study. Castor oil was found not to be mutagenic or clastogenic in several in vitro genetic toxicity assays, and administration of diets containing up to 10% castor oil was not associated with toxicity to any specific organ, organ system, or tissue in this study

\* IUCLID

Ex TITANIUM DIOXIDE rai

Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of

appropriate studies using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies.

Skin Irritation/Corrosion

Serious Eye Damage/Irritation

×

#### Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. For titanium dioxide: Humans can be exposed to titanium dioxide via inhalation, ingestion or dermal contact. In human lungs, the clearance kinetics of titanium dioxide is poorly characterized relative to that in experimental animals. (General particle characteristics and host factors that are considered to affect deposition and retention patterns of inhaled, poorly soluble particles such as titanium dioxide are summarized in the monograph on carbon black.) With regard to inhaled titanium dioxide, human data are mainly available from case reports that showed deposits of titanium dioxide in lung tissue as well as in lymph nodes. A single clinical study of oral ingestion of fine titanium dioxide showed particle size-dependent absorption by the gastrointestinal tract and large interindividual variations in blood levels of titanium dioxide. Studies on the application of sunscreens containing ultrafine titanium dioxide to healthy skin of human volunteers revealed that titanium dioxide particles only penetrate into the outermost layers of the stratum corneum, suggesting that healthy skin is an effective barrier to titanium dioxide. There are no studies on penetration of titanium dioxide in compromised skin. Respiratory effects that have been observed among groups of titanium dioxide-exposed workers include decline in lung function, pleural disease with plaques and pleural thickening, and mild fibrotic changes. However, the workers in these studies were also exposed to asbestos and/or silica. No data were available on genotoxic effects in titanium dioxide-exposed humans. Many data on deposition, retention and clearance of titanium dioxide in experimental animals are available for the inhalation route. Titanium dioxide inhalation studies showed differences — both for normalized pulmonary burden (deposited mass per dry lung, mass per body weight) and clearance kinetics - among rodent species including rats of different size, age and strain. Clearance of titanium dioxide is also affected by pre-exposure to gaseous pollutants or co-exposure to cytotoxic aerosols. Differences in dose rate or clearance kinetics and the appearance of focal areas of high particle burden have been implicated in the higher toxic and inflammatory lung responses to intratracheally instilled vs inhaled titanium dioxide particles. Experimental studies with titanium dioxide have demonstrated that rodents experience dose-dependent impairment of alveolar macrophage-mediated clearance. Hamsters have the most efficient clearance of inhaled titanium dioxide. Ultrafine primary particles of titanium dioxide are more slowly cleared than their fine counterparts. Titanium dioxide causes varying degrees of inflammation and associated pulmonary effects including lung epithelial cell injury, cholesterol granulomas and fibrosis. Rodents experience stronger pulmonary effects after exposure to ultrafine titanium dioxide particles compared with fine particles on a mass basis. These differences are related to lung burden in terms of particle surface area, and are considered to result from impaired phagocytosis and sequestration of ultrafine particles into the interstitium. Fine titanium dioxide particles show minimal cytotoxicity to and inflammatory/pro-fibrotic mediator release from primary human alveolar macrophages in vitro compared with other particles. Ultrafine titanium dioxide particles inhibit phagocytosis of alveolar macrophages in vitro at mass dose concentrations at which this effect does not occur with fine titanium dioxide. In-vitro studies with fine and ultrafine titanium dioxide and purified DNA show induction of DNA damage that is suggestive of the generation of reactive oxygen species by both particle types. This effect is stronger for ultrafine than for fine titanium oxide, and is markedly enhanced by exposure to simulated sunlight/ultraviolet light. Animal carcinogenicity data Pigmentary and ultrafine titanium dioxide were tested for carcinogenicity by oral administration in mice and rats, by inhalation in rats and female mice, by intratracheal administration in hamsters and female rats and mice, by subcutaneous injection in rats and by intraperitoneal administration in male mice and female rats. In one inhalation study, the incidence of benign and malignant lung tumours was increased in female rats. In another inhalation study, the incidences of lung adenomas were increased in the high-dose groups of male and female rats. Cystic keratinizing lesions that were diagnosed as squamous-cell carcinomas but re-evaluated as non-neoplastic pulmonary keratinizing cysts were also observed in the high-dose groups of female rats. Two inhalation studies in rats and one in female mice were negative. Intratracheally instilled female rats showed an increased incidence of both benign and malignant lung tumours following treatment with two types of titanium dioxide. Tumour incidence was not increased in intratracheally instilled hamsters and female mice. In-vivo studies have shown enhanced micronucleus formation in bone marrow and peripheral blood lymphocytes of intraperitoneally instilled mice. Increased Hprt mutations were seen in lung epithelial cells isolated from titanium dioxide-instilled rats. In another study, no enhanced oxidative DNA damage was observed in lung tissues of rats that were intratracheally instilled with titanium dioxide. The results of most in-vitro genotoxicity studies with titanium dioxide were negative The material may produce moderate eye irritation leading to inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. CARBON BLACK Inhalation (rat) TCLo: 50 mg/m3/6h/90D-I Nil reported **CASTOR OIL & TITANIUM** No significant acute toxicological data identified in literature search. DIOXIDE & CARBON BLACK The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a 2,6-BIS(METHYLTHIO)clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested. 4-METHYLp-Phenylenediamines are oxidised by the liver microsomal enzymes (S9). Pure p-phenylenediamine is non-mutagenic in but becomes mutagenic 1,3-BENZENEDIAMINE & after it is oxidized. Azo dyes containing phenylenediamine are mutagenic in certain assay most likely due to the formation of oxidized 4,6-BIS(METHYLTHIO)p-phenylenediamine. Modification of the moieties that can be metabolized to p-phenylenediamine by sulfonation, carboxylation or copper 2-METHYLcomplexation eliminated the mutagenic responses 1,3-BENZENEDIAMINE Rats given di(methylthio)toluenediamines in the diet for up to 90 days showed increased liver metabolic activity. There were kidney effects observed that were unique to male rats. These effects were similar to changes that have been observed in male rats given hydrocarbons. These effects resolved in animals allowed 30 days recovery. Rats treated for 24 months did not have microscopic alterations in any tissues compared to control animals. Tumors seen in control and treated animals were unusual for the age and strain of rats. NOTE: Substance has been shown to be mutagenic in at least one assay, or belongs to a family of chemicals producing damage or change to cellular DNA. TITANIUM DIOXIDE & CARBON BLACK WARNING: This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans. Acute Toxicity X Carcinogenicity ~

Continued...

×

~

Reproductivity

STOT - Single Exposure

Respiratory or Skin sensitisation	¥	STOT - Re	peated Exposure	×
Mutagenicity	¥	A	spiration Hazard	×
		Legend: X – Data either not available or does not fill the criteria for classification – Data available to make classification		

SECTION 12 Ecological information

Τοχ	icitv
IOX	icity

	Endpoint	Test Duration (hr)	Species		Value	Source
Ardex RA 54 Part B	Not Available	Not Available	Not Available		Not Available	Not Available
	Endpoint	Test Duration (hr)	Species		Value	Source
	NOEC(ECx)	24h	Crustacea	Crustacea 100mg/l		2
castor oil	EC50	72h	Algae or other aquatic plants		>100mg/l	2
	EC50	48h	Crustacea		100mg/l	2
	Endpoint	Test Duration (hr)	Species		Value	Source
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	Not Available	Not Available	Not Available		Not Available	Not Available
	Endpoint	Test Duration (hr)	Species		Value	Source
	BCF	1008h	Fish	Fish <1.1-9.6		7
	LC50	96h	Fish	Fish 1.85-3.06mg		4
titanium dioxide	EC50	72h	Algae or other aquatic plants	Algae or other aquatic plants 3.75-7.58mg		4
	EC50	48h	Crustacea	Crustacea 1.9mg/l		2
	EC50	96h	Algae or other aquatic plants	Algae or other aquatic plants 179.05mg/l		2
	NOEC(ECx)	504h	Crustacea	Crustacea 0.02mg/l		4
	Endpoint	Test Duration (hr)	Species		Value	Source
4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	Not Available	Not Available	Not Available		Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Valu	e	Source
	LC50	96h	Fish	>100	)mg/l	2
carbon black	EC50	72h	Algae or other aquatic plants	>0.2	mg/l	2
	EC50	48h	Crustacea	Crustacea 33.076-41.968n		4
	NOEC(ECx)	24h	Crustacea	3200	)mg/l	1
Legend:	Ecotox databas	, , , , , , , , , , , , , , , , , , ,	CHA Registered Substances - Ecotoxicological I C Aquatic Hazard Assessment Data 6. NITE (Jaj	,		,

DO NOT discharge into sewer or waterways.

# Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
titanium dioxide	HIGH	HIGH

# **Bioaccumulative potential**

Ingredient	Bioaccumulation
titanium dioxide	LOW (BCF = 10)
Mobility in soil	

Ingredient	Mobility
titanium dioxide	LOW (KOC = 23.74)

# **SECTION 13 Disposal considerations**

Waste treatment methods		
Product / Packaging disposal	<ul> <li>Containers may still present a chemical hazard/ danger when empty.</li> <li>Return to supplier for reuse/ recycling if possible.</li> <li>Otherwise:</li> <li>If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.</li> <li>Where possible retain label warnings and SDS and observe all notices pertaining to the product.</li> </ul>	

DO NOT allow wash water from cleaning or process equipment to enter drains.
It may be necessary to collect all wash water for treatment before disposal.
In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
Where in doubt contact the responsible authority.
Recycle wherever possible or consult manufacturer for recycling options.
Consult State Land Waste Authority for disposal.
Bury or incinerate residue at an approved site.
Recycle containers if possible, or dispose of in an authorised landfill.

### **SECTION 14 Transport information**

Labels Required		
Marine Pollutant	NO	
HAZCHEM	Not Applicable	

## Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

#### Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

## Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
castor oil	Not Available
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	Not Available
titanium dioxide	Not Available
4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	Not Available
carbon black	Not Available

#### Transport in bulk in accordance with the IGC Code

Product name	Ship Type
castor oil	Not Available
2,6-bis(methylthio)-4-methyl- 1,3-benzenediamine	Not Available
titanium dioxide	Not Available
4,6-bis(methylthio)-2-methyl- 1,3-benzenediamine	Not Available
carbon black	Not Available

## **SECTION 15 Regulatory information**

#### Safety, health and environmental regulations / legislation specific for the substance or mixture

# castor oil is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

## 2,6-bis(methylthio)-4-methyl-1,3-benzenediamine is found on the following regulatory lists Not Applicable

### titanium dioxide is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)	Internationa
Chemical Footprint Project - Chemicals of High Concern List	Monograph
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC	Internationa Manufacture
Monographs	Manufactur

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

# 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine is found on the following regulatory lists Not Applicable

### carbon black is found on the following regulatory lists Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals Australian Inventory of Industrial Chemicals (AIIC) Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

#### **National Inventory Status**

National Inventory	Status	
Australia - AIIC / Australia	No (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	

National Inventory	Status	
Non-Industrial Use		
Canada - DSL	No (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
Canada - NDSL	No (castor oil; carbon black)	
China - IECSC	Yes	
Europe - EINEC / ELINCS / NLP	No (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
Japan - ENCS	o (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
Korea - KECI	lo (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
New Zealand - NZIoC	Yes	
Philippines - PICCS	Yes	
USA - TSCA	Yes	
Taiwan - TCSI	Yes	
Mexico - INSQ	No (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
Vietnam - NCI	Yes	
Russia - FBEPH	No (2,6-bis(methylthio)-4-methyl-1,3-benzenediamine; 4,6-bis(methylthio)-2-methyl-1,3-benzenediamine)	
Legend:	<ul> <li>Yes = All CAS declared ingredients are on the inventory</li> <li>No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.</li> </ul>	

#### **SECTION 16 Other information**

Revision Date	10/03/2023
Initial Date	19/05/2016

### **SDS Version Summary**

Version	Date of Update	Sections Updated
7.1	23/12/2022	Classification review due to GHS Revision change.
8.1	10/03/2023	Classification change due to full database hazard calculation/update.

#### Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### Definitions and abbreviations

PC - TWA: Permissible Concentration-Time Weighted Average PC - STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit. IDLH: Immediately Dangerous to Life or Health Concentrations ES: Exposure Standard OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index AIIC: Australian Inventory of Industrial Chemicals DSL: Domestic Substances List NDSL: Non-Domestic Substances List IECSC: Inventory of Existing Chemical Substance in China EINECS: European INventory of Existing Commercial chemical Substances ELINCS: European List of Notified Chemical Substances NLP: No-Longer Polymers ENCS: Existing and New Chemical Substances Inventory KECI: Korea Existing Chemicals Inventory NZIoC: New Zealand Inventory of Chemicals PICCS: Philippine Inventory of Chemicals and Chemical Substances TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory INSQ: Inventario Nacional de Sustancias Químicas NCI: National Chemical Inventory FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.